

DAFTAR PUSTAKA

- (KEMENKES), K. K. (2020). Laporan Nasional Riskesdas 2018. *Badan Litbangkes*.
- (WHO)., W. H. (2024). Global Report on Diabetes Prevention and Control: Integrating Quality of Life Measures in Health Economic Assessments. *Geneva: WHO Press*.
- Aminah, S. P. (2023). Urban lifestyle and the rising prevalence of type 2 diabetes mellitus in major Indonesian cities. . *Journal of Public Health and Community Medicine*, 12(2), 145–154.
- Antoni, M. (2023). Terapi Diabetes Melitus Tipe 2 Berbasis Hormon Inkretin. . *Jurnal Kedokteran Meditek*, 29(2).
- Azzahra Utomo, N. W. (2020). Komplikasi Kronis Diabetes Melitus dan Mekanisme Terjadinya. *Journal of Endocrinology and Metabolism Review*, 5(2), 112–120.
- Barzilai, N. F. (2022). Incretin-based therapies for the management of Type 2 Diabetes in older adults. *Journal of Diabetes and its Complications*, 36(4), 108140.
- Brazier, J. R. (2023). Integrating Disease-Specific Quality of Life Measures into QALY Calculations: Applications in Diabetes. . *Health Economics Review*, 13(1), 12–25.
- Budi, R. A. (2023). Genetic predisposition and familial risk factors in type 2 diabetes mellitus. *Indonesian Journal of Clinical Endocrinology*, 5(1), 33–41.
- Budianto, R. H. (2024). Analisis ICUR dalam Terapi Antidiabetik Tipe 2: Perbandingan Biaya dan Kualitas Hidup. . *Jurnal Ekonomi dan Kesehatan*, 10(2), 55–68.
- Bujang, M. A. (2018). Quality of life among patients with type 2 diabetes: A systematic review. *Journal of Diabetes Research*, 2018, 1–9.
- Dayaningsih, W. R. (2021). Pathophysiology and Clinical Manifestations of Type 2 Diabetes Mellitus. . *International Journal of Medical and Health Sciences*, 15(4), 45–52.
- Devlin, N. J. (2020). Using Disease-Specific Quality of Life Measures to Adjust QALYs in Diabetes Health Economic Evaluations. *Value in Health*, 23(8), 1050–1059.
- Drummond, M. F. (2015). Methods for the Economic Evaluation of Health Care Programmes (4th ed.). In M. F. Drummond. Oxford University Press.

- Fadilah, N. W. (2022). Age-related increase in type 2 diabetes mellitus prevalence in Indonesian adults. . *Journal of Metabolic and Degenerative Diseases*, 7(3), 201–210.
- Galicia-Garcia, U. B.-V.-S. (2020). Pathophysiology of Type 2 Diabetes Mellitus. . *International Journal of Molecular Sciences*, 21(17).
- Glasgow, R. E. (2021). Diabetes Quality of Life (DQOL) as a Component for QALY Assessment in Type 2 Diabetes. *Diabetes Care*, 44(6), 1372–1381.
- Gold, M. R. (2000). Cost Utility. In M. R. Gold, *Cost-Effectiveness in Health and Medicine*. Oxford University Press.
- Gong, L. G. (2021). Metformin: Mechanisms of action and clinical applications. *Pharmacogenetics and Genomics*, 31(5), 101–112.
- González-Muniesa, P. B. (2020). Obesity as an inflammatory disease. . *Obesity Reviews*, 21(11), e13071.
- Gunawan, T. P. (Jurnal Ilmu Kesehatan). Pengaruh Aktivitas Fisik terhadap Sensitivitas Insulin dan Kendali Glikemik pada Pasien DM Tipe 2. . *Jurnal Ilmu Kesehatan*, 12(3), 78–88.
- Khan, M. A. (2020). Epidemiology of Type 2 Diabetes – Global Burden and Progression. . *International Journal of Clinical Practice*, 74(3), e13512.
- Khan, M. A. (2020). Epidemiology of Type 2 Diabetes—Global Burden and Complications. *International Journal of Clinical Practice*, 74(3), e13512.
- Khin, P. P. (2023.). Pancreatic Beta-cell Dysfunction in Type 2 Diabetes. . *Journal of Endocrinology & Diabetes*.
- Komang, A. W. (2023). Determinants of poor quality of life in Indonesian patients with type 2 diabetes mellitus. *Public Health Indonesia*, 9(1), 55–63.
- Latifah, N. F. (2024). Pengaruh Penurunan Berat Badan terhadap Resistensi Insulin dan Efektivitas Terapi Antidiabetik. *Jurnal Kedokteran dan Kesehatan*, 19(1), 33–44.
- Lu, X. C. (2024.). Type 2 Diabetes Mellitus in Adults: Pathogenesis, Mechanisms and Management. *Signal Transduction and Targeted Therapy*.
- Mahajan, A. e. (2022). Fine-mapping type 2 diabetes loci to single-variant resolution using high-Density imputation and islet-specific epigenome maps. . *Nature Genetics*, 54(4), 390–402.
- Munawarah, S. M. (2024). Evaluation of health-related quality of life in type 2 diabetes patients receiving oral antidiabetic therapy. . *Clinical Diabetes Journal*, 6(1), 23–31.

- Ohiagu, F. O. (2021). Pathophysiology of diabetes mellitus complications: Metabolic events and control. . *Biomedical Research and Therapy*, 8(3), 4243–4257.
- Pebriani, A. L. (2024). Self-care management and its association with quality of life in type 2 diabetes patients. . *Diabetes Care and Therapy Journal*, 5(2), 101–109.
- Polonsky, W. H. (2023). Impact of Insulin Pump Therapy on DQOL and QALY in Patients with Type 2 Diabetes. . *Diabetes Technology & Therapeutics*, 25(4), 245–256.
- Pradana, R. W. (2022). Global diabetes burden and its impact on public health policy. . *Global Health Science Review*, 4(1), 1–10.
- Prakoso, B. H. (2023). Analisis Cost-Utility Terapi Antidiabetik di Rumah Sakit Daerah: Perbandingan Metformin dan Sitagliptin. . *Jurnal Manajemen Kesehatan Indonesia*, 18(2), 65–78.
- Pramudita, F. S. (2023). Evaluasi Cost-Utility Terapi Antidiabetik pada Pasien Diabetes Melitus Tipe 2. *Jurnal Farmasi dan Kesehatan*, 12(1), 23–35.
- Priyanto, A. S. (2022). Autoimmune Mechanisms and β -Cell Destruction in Type 1 Diabetes. . *Medical Research Archives*, 10(6), 1–12.
- Putri, D. U. (2021). Health-related quality of life among type 2 diabetes patients using HRQoL instruments. . *Journal of Clinical Pharmacy and Therapeutics*, 46(4), 987–995.
- Rahmawati, D. H. (2022). Peran Edukasi dan Intervensi Gaya Hidup pada Pengelolaan Diabetes Melitus Tipe 2. *Jurnal Kesehatan Masyarakat Indonesia*, 17(2), 105–114.
- Rediningsih, D. &. (2022). Insulin Resistance Mechanisms in Type 2 Diabetes Mellitus. . *Journal of Diabetes and Endocrine Disorders*, 7(1), 55–63.
- Rena, G. H. (2020). Metformin sebagai Terapi Lini Pertama pada Diabetes Melitus Tipe 2: Efektivitas, Keamanan, dan Biaya. . *Jurnal Farmasi dan Terapi*, 15(3), 210–221.
- Rena, G. H. (2020). The mechanisms of action of metformin. *Diabetologia*, 63(9), 1523–1533.
- Saeedi, P. e. (2021). Global and regional diabetes prevalence estimates for 2021 and projections for 2045. *Diabetes Research and Clinical Practice*, 183, 109119.
- Saeedi, P. P. (2021). Global and Regional Diabetes Prevalence Estimates for 2021 and Projections for 2045. . *Diabetes Research and Clinical Practice*, 183, 109119.
- Sari, N. H. (2022). Analisis ICUR dan Evaluasi Efektivitas Biaya Terapi Antidiabetik di Indonesia: Implikasi untuk Kebijakan Kesehatan Nasional. *Jurnal Manajemen Kesehatan Indonesia*, 17(3), 45–58.

- Savitri, L. P. (2023). Efektivitas Terapi Gizi Medis terhadap Kendali Glikemik pada Pasien Diabetes Melitus Tipe 2. . *Jurnal Gizi Klinik Indonesia*, 16(1), 45–56.
- Scheen, A. J. (2021). A review of DPP-4 inhibitors used in the management of Type 2 Diabetes. *Clinical Pharmacology & Therapeutic*, 110(6), 1424–1438.
- Sudirman, H. Y. (2024). Population aging, urbanization, and dietary transition as drivers of type 2 diabetes prevalence. . *Asia-Pacific Journal of Preventive Medicine*, 16(1), 88–96.
- Wardana, W. H. (2022). Pemantauan Gula Darah Mandiri pada Pasien Diabetes Melitus Tipe 2: Evaluasi Intervensi Gaya Hidup dan Penyesuaian Terapi Farmakologis. . *Jurnal Klinik Diabetes*, 9(2), 101–112.
- Weir, G. C.-W. (2020). Progression of β -cell failure in type 2 diabetes. . *Current Diabetes Reports*, 20(3), 26.
- Wulandari, S. P. (2023). Evaluasi Cost-Utility Penggunaan Insulin dan Metformin pada Pasien Diabetes Melitus Tipe 2. . *Jurnal Farmasi dan Kesehatan*, 13(2), 78–89.
- Yunus, A. H. (2024). Sitagliptin sebagai Alternatif Terapi pada Diabetes Melitus Tipe 2: Mekanisme, Efektivitas, dan Profil Keamanan. . *Jurnal Endokrinologi dan Metabolisme*, 11(1), 12–24.
- Zheng, Y. L. (2022). Global burden of type 2 diabetes and its complications. . *Nature Reviews Endocrinology*, 18, 60–75.
- Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia : report of a WHO/IDF consultation.* (2006). World Health Organization.
- Endokrinologi Indonesia Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2, P. (n.d.). Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 *Dewasa Di Indonesia-2021*. Penerbit PB. PERKENI.
- Health Organization, W. (2025). *Regional Commemoration of World Diabetes Day 2024 Ministry of Health Sri Lanka*. <http://apps.who.int/bookorders>.
- Kebijakan Pembangunan, B., Kementerian, K., & Ri, K. (n.d.). *Dalam Angka Tim Penyusun SKI 2023 Dalam Angka Kementrian Kesehatan Republik Indonesia*.
- Penderita, J., Melitus, D., Kabupaten, B., Kota, /, & Barat, J. (n.d.). *Judul Dataset*.
- Pratiwi, J. A. D., Huang, C. T., Juber, N. F., & Liu, J. J. (2024). Associations between diabetes mellitus and subsequent non-communicable diseases in Indonesia. *Discover Social Science and Health*, 4(1). <https://doi.org/10.1007/s44155-024-00086-0>

SAMBUTAN Puji dan syukur kami panjatkan kepada Allah SWT, K., Yang Maha Esa yang telah melimpahkan rahmat dan hidayahNya sehingga Laporan Kinerja Kementerian Kesehatan, T., &

Kinerja Kementerian Kesehatan merupakan, L. (n.d.). *TENTERI KESEHATAN REPUBLIK INDONESIA Tahun 2022 dapat diselesaikan pada waktunya.*

Yogesh, M., Patel, M., Gandhi, R., Patel, A., & Kidecha, K. N. (2025). Sarcopenia in type 2 Diabetes mellitus among Asian populations: prevalence and risk factors based on AWGS- 2019: a systematic review and meta-analysis. *BMC Endocrine Disorders*, 25(1). <https://doi.org/10.1186/s12902-025-01935-y>